Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% – Time to Sell?

Turn Therapeutics Inc. (NASDAQ:TTRX) dropped 6.5% during mid-day trading on Thursday . The company traded as low as $9.80 and last traded at $9.86. 64,512 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 77,022 shares. The stock had previously closed at $10.54.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TTRX. Weiss Ratings raised shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a report on Monday, July 13th. Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a research note on Saturday, July 18th. Zacks Research raised Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Finally, LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Turn Therapeutics Price Performance

The stock has a market capitalization of $293.71 million and a price-to-earnings ratio of -34.00. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.97. The business’s 50 day simple moving average is $7.95 and its 200-day simple moving average is $5.31.

Turn Therapeutics (NASDAQ:TTRX) last released its earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. On average, research analysts forecast that Turn Therapeutics Inc. will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hodges Capital Management Inc. bought a new stake in Turn Therapeutics during the fourth quarter worth $39,000. LPL Financial LLC bought a new stake in shares of Turn Therapeutics during the fourth quarter worth about $51,000. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $59,000. Composition Wealth LLC acquired a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Jane Street Group LLC bought a new position in Turn Therapeutics in the 4th quarter valued at approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.